Biotechnology Research
Biotechnology Research
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. They have developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data.
AllStripes is a a Public Benefit Corporation and was founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. The company is backed by Lux Capital, JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, Maveron, and a number of angel investors.
"As the leading research platform dedicated to rare diseases, AllStripes makes it easy for patients to contribute to new treatment research from home. We do the work to collect and analyze de-identified medical records to help power faster, better drug development. We partner with rare disease patient advocacy organizations and key opinion leaders to build our programs. Our expert researchers produce original research insights and publications, as well as partner with academic institutions and pharmaceutical companies to make progress towards new treatments."
Also see: Care Access
Braid Health has built the first frictionless infrastructure for healthcare data and collaboration: FDA-cleared, secure, real-time, modality-agnostic, and AI-augmented.
With products in areas of interoperability and care coordination for IDNs (integrated delivery networks), providers, and patients; collaboration for multidisciplinary conferences and tumor boards; AI-supported radiology software and service; and a reimagined data flywheel for clinical trials and Pharma R&D, their mission is the betterment of patient care.
Also see: Radiology Partners
Day One Biopharmaceuticals understands that advances in cancer research now allow drug developers to determine children and adults who may benefit from the same medicine.
Day One is a unique biopharmaceutical company on a mission to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Their distinctive approach, together with their trusted network of pediatric oncology investigators, gives them an unmatched ability to advance promising discoveries for patients of all ages. They are prepared to pursue the full potential of their therapies to improve the greatest number of lives as quickly as possible.
What Day One Biopharmaceuticals says about their mission:
"We’re ready to deliver a lasting impact for children with cancer by making sure modern targeted treatments can get to those who need them most. How? Through our deep understanding of biology and the pediatric community. We have a purposeful approach to drug development. And the right mix of people, experience and skills to drive real lasting change. We’re ready to introduce new ground-breaking treatments. Ready to be dedicated, long-term partners. Ready to solve the challenges faced by children with cancer."
Also see: Parexel International
